ATE282416T1 - Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen - Google Patents
Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungenInfo
- Publication number
- ATE282416T1 ATE282416T1 AT97952023T AT97952023T ATE282416T1 AT E282416 T1 ATE282416 T1 AT E282416T1 AT 97952023 T AT97952023 T AT 97952023T AT 97952023 T AT97952023 T AT 97952023T AT E282416 T1 ATE282416 T1 AT E282416T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- receptor antagonists
- disorders
- substance
- substance use
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9625051A GB9625051D0 (en) | 1996-12-02 | 1996-12-02 | Therapeutic agents |
GB9701459A GB9701459D0 (en) | 1997-01-24 | 1997-01-24 | Therapeutic agents |
GB9713715A GB9713715D0 (en) | 1997-06-27 | 1997-06-27 | Therapeutic agents |
GBGB9717097.1A GB9717097D0 (en) | 1997-08-12 | 1997-08-12 | Therapeutic agents |
PCT/EP1997/006690 WO1998024444A1 (en) | 1996-12-02 | 1997-11-25 | Use of nk-1 receptor antagonists for treating substance use disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE282416T1 true ATE282416T1 (de) | 2004-12-15 |
Family
ID=27451570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97952023T ATE282416T1 (de) | 1996-12-02 | 1997-11-25 | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen |
Country Status (9)
Country | Link |
---|---|
US (1) | US5919781A (de) |
EP (1) | EP0942731B1 (de) |
JP (1) | JP2001504853A (de) |
AT (1) | ATE282416T1 (de) |
AU (1) | AU731674B2 (de) |
CA (1) | CA2273806A1 (de) |
DE (1) | DE69731657T2 (de) |
ES (1) | ES2231901T3 (de) |
WO (1) | WO1998024444A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6271230B1 (en) * | 1997-12-01 | 2001-08-07 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating cognitive disorders |
US6087348A (en) * | 1997-12-01 | 2000-07-11 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating stress disorders |
WO1999064010A1 (en) * | 1998-06-11 | 1999-12-16 | Merck Sharp & Dohme Limited | Use of a nk-1 receptor antagonist for treating psychiatric disorders |
AU4278199A (en) * | 1998-06-11 | 1999-12-30 | Merck Sharp & Dohme Limited | Use of a nk-1 receptor antagonist for treating psychiatric disorders |
US20060205724A1 (en) * | 2002-05-29 | 2006-09-14 | The Regents Of The University Of California | Antagonizing nk-1 receptors inhibits consumption of substances of abuse |
GB2394417A (en) * | 2002-10-24 | 2004-04-28 | Novartis Ag | Solid dispersion comprising a piperidine substance P antagonist and a carrier |
US20050065175A1 (en) * | 2003-09-24 | 2005-03-24 | Xanodyne Pharmacal, Inc. | Oral transmucosal methadone |
WO2008090117A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990005525A1 (en) * | 1988-11-23 | 1990-05-31 | Pfizer Inc. | Quinuclidine derivatives as substance p antagonists |
PT533280E (pt) * | 1991-09-20 | 2001-01-31 | Glaxo Group Ltd | Novas utilizacoes medicas para antagonistas de taquiquinina |
US5719147A (en) * | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
CA2099233A1 (en) * | 1992-06-29 | 1993-12-30 | Conrad P. Dorn | Morpholine and thiomorpholine tachykinin receptor antagonists |
AU6226494A (en) * | 1993-03-04 | 1994-09-26 | Pfizer Inc. | Spiroazacyclic derivatives as substance p antagonists |
US5496833A (en) * | 1993-04-13 | 1996-03-05 | Merck Sharp & Dohme Limited | Piperidine tachykinin receptor antagonists |
IL111002A (en) * | 1993-09-22 | 1998-09-24 | Glaxo Group Ltd | History of piperidine, their preparation and the pharmaceutical preparations containing them |
SG52217A1 (en) * | 1993-12-29 | 1998-09-28 | Merck Sharp & Dohme | Substituted morpholine derivatives and their use as therapeutic agents |
WO1996005181A1 (en) * | 1994-08-15 | 1996-02-22 | Merck Sharp & Dohme Limited | Morpholine derivatives and their use as therapeutic agents |
GB9426103D0 (en) * | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Therapeutic agents |
WO1996024353A1 (en) * | 1995-02-10 | 1996-08-15 | Eli Lilly And Company | Methods of treating or preventing psychiatric disorders |
-
1997
- 1997-11-25 CA CA002273806A patent/CA2273806A1/en not_active Abandoned
- 1997-11-25 AT AT97952023T patent/ATE282416T1/de not_active IP Right Cessation
- 1997-11-25 ES ES97952023T patent/ES2231901T3/es not_active Expired - Lifetime
- 1997-11-25 EP EP97952023A patent/EP0942731B1/de not_active Revoked
- 1997-11-25 JP JP52517598A patent/JP2001504853A/ja not_active Ceased
- 1997-11-25 AU AU55593/98A patent/AU731674B2/en not_active Ceased
- 1997-11-25 WO PCT/EP1997/006690 patent/WO1998024444A1/en active IP Right Grant
- 1997-11-25 DE DE69731657T patent/DE69731657T2/de not_active Expired - Fee Related
- 1997-12-01 US US08/980,927 patent/US5919781A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2273806A1 (en) | 1998-06-11 |
ES2231901T3 (es) | 2005-05-16 |
DE69731657D1 (de) | 2004-12-23 |
DE69731657T2 (de) | 2005-12-01 |
AU5559398A (en) | 1998-06-29 |
WO1998024444A1 (en) | 1998-06-11 |
AU731674B2 (en) | 2001-04-05 |
EP0942731B1 (de) | 2004-11-17 |
US5919781A (en) | 1999-07-06 |
EP0942731A1 (de) | 1999-09-22 |
JP2001504853A (ja) | 2001-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60133029D1 (de) | Mittel zur prävention oder behandlung von psoriasi | |
MX9703186A (es) | Antagonistas del receptor del neuropeptido y de indolilo. | |
DE69508093D1 (de) | Substituierte piperidine für die behandlung von allergischen krankheiten | |
DE60022050D1 (de) | Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems | |
ATE269336T1 (de) | Steroidrezeptor-modulator verbindungen und methoden | |
MX9602818A (es) | Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige. | |
TR199802273T2 (xx) | Fibrotik lezyonlar�n onar�lmas� ve �nlenmesi. | |
EP0548250A4 (en) | Substituted bicyclic aryl compounds exhibiting selective leukotriene b 4? antagonist activity | |
DE59810761D1 (de) | Verwendung von vasopressin-antagonisten zur behandlung von störungen oder erkrankungen des innenohres | |
NO994850L (no) | Farmakologiske midler | |
DE69917230D1 (de) | Kombinationspräparat, das selektive nmda nr2b-antagonisten und cox-2 inhibitoren enthält | |
NO975975L (no) | Vitronektinreseptor-antagonister, fremstilling samt anvendelse derav | |
ATE282417T1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen | |
ATE381533T1 (de) | Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung | |
ATE303362T1 (de) | Chalcon-derivate mit antiproliferativer aktivität | |
NZ300942A (en) | 1-aryl-2-acylamino-ethane derivatives as neurokinin 1 antagonists | |
ATE282416T1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen | |
SE9903995D0 (sv) | New combination | |
DE69808475D1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
ATE293975T1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von kognitiven störungen | |
DE69732133D1 (de) | Verfahren und vorrichtung zur kompensation von durch chrominanzsignalverarbeitung verursachten luminanzstörungen | |
DE69732492D1 (de) | Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden | |
TR199900480T2 (xx) | Kristalin farmas�tik �r�n. | |
DE69730515D1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlungen von stress störungen | |
HUP9900606A2 (hu) | 5-HT3 Receptor antagonisták mozgászavar kezelésére |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0942731 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee | ||
RZN | Patent revoked |